Evaluating and implementing data and safety monitoring plans

Journal of Investigative Medicine

Volumn 52, Issue 7, 2004, Pages 459-463

  Terrin, Michael L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Data and safety monitoring plan; Monitoring; Patient safety

Indexed keywords

CLINICAL TRIAL; ERROR; EVALUATION; HEALTH CARE PLANNING; INFORMATION PROCESSING; REVIEW; RISK ASSESSMENT; SAFETY;

EID: 11244319579     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.1136/jim-52-07-38     Document Type: Review

References (21)

1. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: ethical principles and guidelines for the protection of human subjects of research. OPPR Reports. 1979.
2. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Protection of human subjects. OPPR Reports. 1994.
3. Knatterud G, Meinert C, Klimt C, et al. Effects of hypoglycemic agents on vascular complications in patient with adult-onset diabetes: IV. A preliminary report on phen-formin results. JAMA 1971;217:777-84.
4. Coronary Drug Project Research Group. The Coronary Drug Project: initial findings leading to modifications of its research protocol. JAMA 1970;214:1303-13.
5. National Cancer Institute. Data and safety monitoring example plans - 2002. Available at: http://www.cancer.gov/clinicaltrials/conducting/dsm-example- plans.
6. Ellenberg S, Fleming TR, DeMets DL. Data monitoring committees in clinical trials: a practical perspective. Chichester (UK): John Wiley: 2002.
7. Fleming TR, DeMets DL. Monitoring of clinical trials: issues and recommendations. Control Clinical Trials 1993;14:183-97.
8. Wittes J. Forming your phase 111 trial's data and safety monitoring board: a perspective on safety. J Invest Med 2004;52:453-8.
9. National Heart, Lung, and Blood Institute. NHLBI investigator initiated clinical trials guidelines - 2003. Available at: http://www.nhlbi.nih.gov/ funding/policies/clinical.htm.
10. Canner P. Monitoring long-term clinical trials for beneficial and adverse treatment effects. Commun Statist Theor Meth 1984;13:2369-94.
11. Thrombolysis in Myocardial Infarction Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N Engl J Med 1989;320:618-27.
12. Paganini-Hill A, Chao A. Accuracy of recall of hip fracture, heart attack, and cancer: a comparison of postal survey data and medical records. Am J Epidemiol 1993;138:101-6.
13. Madow WG. Interview data on chronic conditions compared with information derived from medical records - National Center for Health Statistics report, series 2, number 23. US Department of Health, Education and Welfare; 1967.
14. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
15. Gore J, Sloan M, Price T, et al, and the TIMI Investigators. Intracranial hemorrhage, cerebral infarction, and subdural hematoma following acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study (TIMI II pilot and randomized clinical trial). Circulation 1991;83:448-59.
16. Bovill E, Terrin ML, Stump DC, et al, for the TIMI Investigators. Hemorrhagic events during treatment with intravenous recombinant tissue-type plasminogen activator, heparin and aspirin in acute myocardial infarction (TIMI) phase II trial. Ann Intern Med 1991;115:256-65.
17. Canner P. Monitoring treatment differences in long-term clinical trials. Biometrics 1977;33:603-15.
18. Terrin M. Efficient use of end points in clinical trials: a clinical perspective. Stat Med 1990;9:155-60, 170-2.
19. Charache S, Terrin ML, Moore R, et al, and the Investigators of the Multicenter Study of Hydroxyurea. Design of the Multicenter Study of Hydroxyurea. Control Clin Trials 1995;16:432-46.
20. Fleiss L, Bigger JT, McDermott M, et al. Nonfatal myocardial infarction is, by itself, an inappropriate end point in clinical trials in cardiology Circulation 1990;81:684-5.
21. Lubsen J, Kirwan BA. Combined endpoints: can we use them? Stat Med 2002;21:2959-70.